RTW Investments LP raised its position in Vericel Corp (NASDAQ:VCEL) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,289,134 shares of the biotechnology company’s stock after purchasing an additional 71,218 shares during the quarter. Vericel accounts for about 3.7% of RTW Investments LP’s holdings, making the stock its 8th biggest holding. RTW Investments LP owned about 5.28% of Vericel worth $39,831,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Perceptive Advisors LLC raised its position in Vericel by 3.2% in the fourth quarter. Perceptive Advisors LLC now owns 28,090 shares of the biotechnology company’s stock valued at $488,000 after purchasing an additional 879 shares during the last quarter. Legal & General Group Plc raised its position in Vericel by 17.1% in the third quarter. Legal & General Group Plc now owns 6,443 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 943 shares during the last quarter. Meeder Asset Management Inc. raised its position in Vericel by 28.7% in the fourth quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 1,284 shares during the last quarter. Doyle Wealth Management bought a new position in Vericel in the fourth quarter valued at about $35,000. Finally, Commonwealth Equity Services LLC raised its position in Vericel by 10.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 22,625 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 2,114 shares during the last quarter. Hedge funds and other institutional investors own 83.40% of the company’s stock.
Shares of VCEL traded up $0.18 during mid-day trading on Monday, reaching $18.36. 9,083 shares of the company were exchanged, compared to its average volume of 821,185. Vericel Corp has a 52 week low of $8.95 and a 52 week high of $21.00. The company has a market capitalization of $796.41 million, a price-to-earnings ratio of -130.71 and a beta of 3.04.
In related news, CFO Gerard J. Michel sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $20.02, for a total transaction of $200,200.00. Following the completion of the sale, the chief financial officer now owns 122,249 shares of the company’s stock, valued at $2,447,424.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul K. Wotton sold 22,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $16.83, for a total value of $378,675.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $84,150. The disclosure for this sale can be found here. Insiders have sold 58,711 shares of company stock valued at $1,034,580 in the last ninety days. 4.70% of the stock is currently owned by insiders.
Several equities analysts have commented on the company. Zacks Investment Research downgraded Vericel from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Needham & Company LLC downgraded Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective for the company. in a research report on Thursday, February 28th. Oppenheimer initiated coverage on Vericel in a research report on Tuesday, January 29th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, BidaskClub downgraded Vericel from a “buy” rating to a “hold” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $19.58.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/03/25/vericel-corp-vcel-is-rtw-investments-lps-8th-largest-position.html.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
See Also: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corp (NASDAQ:VCEL).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.